Personalized chemo dosing may boost survival in kids with High-Risk leukemia
⭐️ CURE ⭐️
Recruiting now
This nationwide trial is testing whether adjusting chemotherapy intensity based on the amount of leukemia cells remaining after initial treatment (called minimal residual disease, or MRD) can improve outcomes for children and teens with high-risk acute lymphoblastic leukemia (ALL…
Phase: PHASE2 • Sponsor: Jae Wook Lee • Aim: ⭐️ CURE ⭐️
Last updated Jul 31, 2026 00:00 UTC